Krista Fogarty - Lipocine Principal Controller
LPCN Stock | USD 4.70 0.01 0.21% |
Insider
Krista Fogarty is Principal Controller of Lipocine
Age | 56 |
Address | 675 Arapeen Drive, Salt Lake City, UT, United States, 84108 |
Phone | 801 994 7383 |
Web | https://www.lipocine.com |
Krista Fogarty Latest Insider Activity
Tracking and analyzing the buying and selling activities of Krista Fogarty against Lipocine stock is an integral part of due diligence when investing in Lipocine. Krista Fogarty insider activity provides valuable insight into whether Lipocine is net buyers or sellers over its current business cycle. Note, Lipocine insiders must abide by specific rules, including filing SEC forms every time they buy or sell Lipocine'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Krista Fogarty over a month ago Acquisition by Krista Fogarty of 991 shares of Lipocine subject to Rule 16b-3 |
Lipocine Management Efficiency
The company has return on total asset (ROA) of (0.3702) % which means that it has lost $0.3702 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.584) %, meaning that it created substantial loss on money invested by shareholders. Lipocine's management efficiency ratios could be used to measure how well Lipocine manages its routine affairs as well as how well it operates its assets and liabilities. As of the 3rd of May 2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to grow to -0.7. At this time, Lipocine's Total Assets are very stable compared to the past year. As of the 3rd of May 2024, Other Assets is likely to grow to about 4 M, while Net Tangible Assets are likely to drop about 27 M.Similar Executives
Found 10 records | INSIDER Age | ||
Brian Cahill | Eagle Pharmaceuticals | 55 | |
Daniel OConnor | Eagle Pharmaceuticals | 44 | |
Thomas JD | Deciphera Pharmaceuticals LLC | 53 | |
John Kimmet | Eagle Pharmaceuticals | N/A | |
Reiner Nowak | Eagle Pharmaceuticals | N/A | |
Scott Gordon | Silver Spike Investment | 63 | |
Patricio Munoz | Procaps Group SA | 51 | |
Jama Pitman | Deciphera Pharmaceuticals LLC | 44 | |
Gregory Gentile | Silver Spike Investment | 48 | |
Melissa Angelini | Procaps Group SA | N/A |
Management Performance
Return On Equity | -0.58 | ||||
Return On Asset | -0.37 |
Lipocine Leadership Team
Elected by the shareholders, the Lipocine's board of directors comprises two types of representatives: Lipocine inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipocine. The board's role is to monitor Lipocine's management team and ensure that shareholders' interests are well served. Lipocine's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipocine's outside directors are responsible for providing unbiased perspectives on the board's policies.
Richard Ono, Director | ||
Jeffrey Fink, Director | ||
CPA CPA, Co Sec | ||
Stephen Hill, Lead Independent Director | ||
Gregory Bass, Executive Vice President Chief Commercial Officer | ||
Logan Morse, Marketing Sales | ||
John Higuchi, Non-Executive Director | ||
Nachiappan Chidambaram, Senior Development | ||
M MD, Chief Director | ||
Mahesh Patel, Co-Founder, Chairman, CEO and Pres | ||
Krista Fogarty, Principal Controller | ||
Morgan Brown, CFO, Executive Vice President |
Lipocine Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipocine a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | -0.58 | ||||
Return On Asset | -0.37 | ||||
Operating Margin | (12.00) % | ||||
Current Valuation | 3.43 M | ||||
Shares Outstanding | 5.35 M | ||||
Shares Owned By Insiders | 2.91 % | ||||
Shares Owned By Institutions | 8.83 % | ||||
Number Of Shares Shorted | 278.43 K | ||||
Price To Earning | 15.80 X | ||||
Price To Book | 1.47 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipocine. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. To learn how to invest in Lipocine Stock, please use our How to Invest in Lipocine guide.Note that the Lipocine information on this page should be used as a complementary analysis to other Lipocine's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Complementary Tools for Lipocine Stock analysis
When running Lipocine's price analysis, check to measure Lipocine's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipocine is operating at the current time. Most of Lipocine's value examination focuses on studying past and present price action to predict the probability of Lipocine's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipocine's price. Additionally, you may evaluate how the addition of Lipocine to your portfolios can decrease your overall portfolio volatility.
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |
Is Lipocine's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lipocine. If investors know Lipocine will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lipocine listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.14) | Revenue Per Share (0.54) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.58) |
The market value of Lipocine is measured differently than its book value, which is the value of Lipocine that is recorded on the company's balance sheet. Investors also form their own opinion of Lipocine's value that differs from its market value or its book value, called intrinsic value, which is Lipocine's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lipocine's market value can be influenced by many factors that don't directly affect Lipocine's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lipocine's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lipocine is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lipocine's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.